SRXH Company Profile and Key Details

SRx Health Solutions Inc. has 33.20 million shares outstanding. The public float is 5.49 million shares, elevated short interest at 4.44% of float. This equals 697.75 thousand shares. The short ratio is 0.02 days. Institutional investors hold 0.88% of the float. Insiders own 45.69%.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

The stock is currently within 5% of its 52-week low $0.12 and $2.02. With a market capitalization of about $4.30 million, SRx Health Solutions Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.94). Key stats such as the average daily volume over the past year has been around 20.91 million shares, in line with its 52-week average. Headquartered in Tampa, FL, SRx Health Solutions Inc. operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Kent Cunningham, the company employs approximately 444 people and listed since June 16, 2010. SRx Health Solutions Inc. is an integrated Canadian healthcare services provider operating within the specialty healthcare industry.

SRx Health Solutions Inc. trades at a P/E ratio of -0.04, slightly below the S&P 500 average, with a price-to-sales ratio of -0.09 and a price-to-book ratio of 4.58 trading at moderately above to book value. The P/FCF stands at -8.1, also above market averages.

SRx Health Solutions Inc. (NYSE:SRXH) shares are down -24.58% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows SRx Health Solutions Inc. trading at a premium to the broader market with a P/E of -0.04. Our AI forecast model points to short-term weakness (-36.61% over two weeks), a medium-term fall (-92.08% over three months), and a longer-term gain (66.4% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that SRx Health Solutions Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -36.61%, with price expected at $0.08 by February 19, 2026, within a range of $0.06 to $0.11 3-Month Outlook: Projected fall of -92.08%, reaching $0.01 by May 06, 2026, with a range of $0.00 to $0.03. 1-Year Outlook: Projected gain of 66.4%, with price at $0.21 by February 05, 2027, within a range of $0.05 to $0.20.